Parkinson’s disease (PD) treatment could be on the cusp of its first new dopamine agonist strategy in decades, as the FDA nears a decision on the investigational drug tavapadon later this month. If approved, the once-daily oral medication will be the first to selectively and partially activate D1/D5 dopamine receptors…
Read More
Could Tavapadon Change Parkinson’s Care?
